
News|Articles|March 2, 2026
FDA updates in urology: February 2026
Author(s)Hannah Clarke
Fact checked by: Benjamin P. Saylor, Strategic Content Lead
A recap of the FDA submissions and regulatory decisions in urology from February 2026.
Advertisement
Advertisement
Welcome to Urology Times’® monthly FDA update! February’s regulatory news was characterized by updates in the men’s and women’s health space, in addition to a notable milestone in the development of an investigational agent for urothelial carcinoma. At the end of February, the field also saw 2 FDA submissions for belzutifan-based combinations in kidney cancer based on data presented at the 2026
Related to this article

CG Oncology plans to submit a second biologics license application to the FDA for cretostimogene in BCG-unresponsive NMIBC by the end of March 2027

Expert urologists examine how TRAVERSE data and an FDA expert panel prompted proposed label revisions for testosterone therapy as well as what narrowed cardiovascular, prostate, and age-related restrictions mean for evaluating and treating testosterone deficiency.

Vignesh Packiam, MD, discusses optimizing BCG treatment in high-risk NMIBC, including patient selection for combination immunotherapy and treatment-related trade-offs.

A national survey of US military service members and veterans with NMIBC found that more than half were diagnosed by age 50, while 63% reported treatment access barriers.

VOLGA results raise the question of treatment de-intensification in perioperative MIBC care, according to Suzanne B. Merrill, MD, FACS.
Advertisement
Advertisement


